Drug intelligence / Profile preview

cephradine

Development stage
Unknown
Lead developer
Viosera Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

Veoxy is a brand name for cephradine, a first-generation cephalosporin antibiotic manufactured by Berlex Lab International in Pakistan. It is indicated for the treatment of various bacterial infections, including respiratory tract infections (such as tonsillitis, pharyngitis, and lobar pneumonia), urinary tract infections, and skin and soft tissue infections. Cephradine exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. It binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This interference prevents the cross-linkage of peptidoglycan chains, which are essential for bacterial wall strength and rigidity, leading to cell lysis and death. It is effective against a range of Gram-positive organisms, including *Staphylococcus aureus* and *Streptococcus pneumoniae*, as well as some Gram-negative organisms like *Escherichia coli*.

Brand names
VeoxyVelosef
Other names
cefradine
02

Targets

PBP (Penicillin-binding protein family)β-lactamase

Beyond the preview

Go deeper on cephradine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephradine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call